摘要
目的分析CEOP方案治疗非霍奇金淋巴瘤（NHL）患者的近期疗效、远期生存和不良反应。方法回顾性分析121例NHL患者的临床特征及CEOP方案化疗加或不加局部放疗的近期疗效、不良反应和远期生存情况。结果121例NHL患者中,B细胞性NHL83例,占68．6％,外周T或NK细胞性NHL38例,占31．4％;中位年龄53岁;临床分期Ⅰ-Ⅱ期67例,占55．4％;国际预后指数（IPI）评分0-2分108例（89．3％）。121例患者均采用CEOP方案化疗加或不加局部放疗。121例患者均可评价客观疗效,总有效率为90．9％,CR率为71．9％。121例患者共接受CEOP方案化疗471个疗程（中位疗程数4个）,主要不良反应为骨髓抑制,其中Ⅲ-Ⅳ度粒细胞减少为11．9％,Ⅲ-Ⅳ度血小板减少为1．9％,Ⅲ-Ⅳ度贫血为1．1％;脱发46．3％,心脏毒性少见,仅占4．7％,且均为可逆性轻度心电图异常。中位随访时间63（2-116）个月,1、3和5年生存率分别为84．8％、62．7％、55．9％,中位生存期85个月（2-118个月,95％可信区间65-105个月）。结论采用CEOP方案治疗NHL近期疗效、远期生存率均较高,心脏毒性较低,值得临床进一步验证和推广应用。
Objective The aim of this study is to analyse the efficacy and toxicity of CEOP regimen in the treatment of non-Hodgkin＇s lymphoma （NHL）. Methods From January 1995 to December 2000, 121 patients with NHL were treated by CEOP regimen with or without radiotherapy for the involved field. The clinical characteristics, response, toxicity and long-term survival results were analysed retrospectively. Results Of these 121 patients, 83 （68.6%） had B-cell NHL and 38 （31.4%） peripheral T or NK-cell NHL; 55.4% （67/121） had early disease （ stage Ⅰ or Ⅱ）, and 89.3 % （ 108/121 ） had IPI score 0 - 2. The median age was 53 years （range： 7-79 yr）. All patients were treated by CEOP regimen （totally, 471 cycles） with or without radiotherapy. The overall response（OR） rate in this series was 90.9% （ 110/121 ） with a complete remission （CR） rate of 71.9% （87/121） ; whereas the response rate of chemotherapy alone was 88.4% （ 107/121 ） with a CR rate of 67.8% （82/121）. Major toxicity consisted of grade Ⅲ-Ⅳ myelosuppression （11.9%）, neutropenia （1.9%） and thrombocytopenia and anemia （1.1%）. Alopecia was observed in 46.3%. However, cardiotoxicity was mild and reversible. Median follow-up duration in this series was 63 months （range： 2 - 116 months）. The overall 1-, 3- and 5-year survival rate was 84.8% , 62.7% and 55.9%, respectively, with a median survival time of 85 months （2 - 118 months ） . Conclusion Our data show that CEOP regimen combined with or without radiotherapy for the involved field is effective and well tolerated by the patients with non-Hodgkin＇s lymphoma.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2007年第5期391-395,共5页
Chinese Journal of Oncology
